Michael Happich PhD

Michael Happich is the International Health Technology Assessment (HTA) director at Eli Lilly based in Bad Homburg, Germany. He leads a team of HTA & RWE scientists to support international drug launches, HTA submissions, and observational research in the autoimmune, pain, and neurology disease areas. Before joining the industry 13 years ago, he worked at the Helmholtz-Research Center in Munich. He is a lecturer on pharmacoeconomics at the Goethe University Frankfurt and Neubrandenburg University of Applied Sciences.